Helix Acquisition Corp III(HLXC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 25 at 4:00 PM ET (Korea 9/26 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 23.43% | Shs Outstand | 17.8M | Perf Week | 0.14% |
| Market Cap | 0.23B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 16.9M | Perf Month | -2.79% |
| Enterprise Value | 0.23B | PEG | - | EPS next Q | - | Inst Own | 79.45% | Short Float | 0.01% | Perf Quarter | 1.1% |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.02 | Perf Half Y | 3.26% |
| Sales | - | P/B | 1.36 | EPS next 5Y | - | ROA | - | Short Interest | 0.00M | Perf YTD | 3.66% |
| Book/sh | 7.8 | P/C | 107.42 | EPS past 3/5Y | - | ROE | - | 52W High | -5.48% ($11.23) | Perf Year | - |
| Cash/sh | 0.1 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 5% ($10.11) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 1.19% 1.82% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.2 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 12.3 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 46.32 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 12.3 | Sales Q/Q | - | SMA20 | -1.59% ($10.78) | Beta | - | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -0.02% ($10.61) | Rel Volume | 0 | Prev Close | $10.94 |
| Employees | 3 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 2.26% ($10.38) | Avg Volume(3M) | 0.04M | Price | $10.61 |
| IPO | 2026/1/23 | Option/Short | No/Yes | Trades | 14 | Volume | 26 | Change | -2.97% |
Helix Acquisition III is a special purpose acquisition company (SPAC) established with the goal of executing mergers and acquisitions in the healthcare sector, and trades on Nasdaq under the ticker HLXC. Led by a sponsor affiliated with Cormorant Asset Management, the company is structured to provide a public listing pathway by merging with private companies in the biotech, medtech, and life sciences fields.
Over the past 1 year, roughly in the middle
6% below its 1-year high.
Traded less than usual That is 0% of its average volume.
This is not an operating company, so the profitability, valuation, and earnings verdicts are not shown. Separate criteria are in the works.
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 79.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
CHDG <0.01% It ranks #1015 of 1434 in the industry
Based on market cap of $234M.
PEBK#1011 $236M PER 11.8 HLXC#1015 $234M PER - 
FAQ
What kind of company is HLXC?
HLXC belongs to the Financial sector and operates in the Shell Companies industry.
What is the market cap of HLXC?
The market cap of HLXC is approximately $234M, ranking 3,969 within its sector.
What is the 52-week high and low for HLXC?
HLXC has recorded a 52-week high of $11.23 and a low of $10.11.
